CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Find out which option tends to yield steadier income—index funds or bonds—and how to blend them for reliability and growth.
24,934 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Dave & Buster's is blending food, drinks, and arcade play into a growing business model. This analysis breaks down th...
A focused duplex hunt in St. Louis turned into an eight-unit treasure, thanks to bold moves, solid numbers, and a kna...
JPMORGAN Global Research says the AI-related capital spend is not a fleeting hype cycle but a profitable buildout. Th...
Ukrainian strikes on energy assets push Russia into a fresh wave of fuel shortages. Households tighten belts as refin...
An official says Trump is not expected to veto the housing bill, signaling a potential policy path. Markets are weigh...
The auto industry is changing fast, and big, cash-rich automakers may be overlooked. This guide explains why investor...
Salesforce is a powerhouse, but big questions remain about margins and AI-driven pricing. This piece explains why I’m...
A dramatic streaming deal sparks a rally in Paramount Skydance and reshapes the media landscape. This guide breaks do...
Occidental Petroleum shares jump as geopolitical risk and Buffett’s investment strategy collide, fueling questions ab...
Alphabet's AI ambitions are under scrutiny as cloud momentum and big-capex raise the stakes. Here’s what investors sh...
Walmart raises its payout to 0.99 per share, extending a 53-year dividend-raising streak and keeping Dividend King st...